Research Paper Volume 15, Issue 14 pp 7237—7257
Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers
Figure 7. (A) NCAPD2 expression was higher in responders than in nonresponders in urothelial carcinoma patients treated with PD-L1 inhibitor atezolizumab. (B) The Kaplan-Meier survival of NCAPD2 in low- and high-expression treated with PD-1 in melanoma.